10-K: Cytek Biosciences Reports Steep Loss Amid Flat Revenue Growth

Cytek Biosciences reported a significant net loss of $66.5 million in 2025, a sharp increase from the previous year, despite minimal 1% revenue growth.

Summary

• Net loss for fiscal year 2025 was $66.5 million, a substantial increase from $6.0 million in 2024 and $12.1 million in 2023.
• Total revenue, net, increased by only 1% to $201.5 million in 2025, up from $200.5 million in 2024.
• Product revenue decreased by 6% to $144.2 million in 2025, while service revenue increased by 21% to $57.3 million.
• Gross margin declined to 52% in 2025 from 55% in 2024, primarily due to higher tariff costs and increased production overhead from transitioning a manufacturing facility overseas.
• General and administrative expenses surged by 37% to $58.9 million in 2025, mainly due to higher patent litigation expenses, compensation, sales and use tax, and software expenses.
• Research and development expenses decreased by 7% to $36.5 million, reflecting efforts to streamline and focus activities.
• Cash and cash equivalents, restricted cash, and short-term investments decreased to $261.5 million in 2025 from $277.9 million in 2024.
• The company repurchased 3,292,588 shares of common stock for approximately $15.1 million in 2025, with $35.0 million remaining authorized in the program.
• Material weaknesses in internal control over financial reporting identified in 2024 were remediated by December 31, 2025.
• The legal settlement liability with Becton, Dickinson and Company was reduced by $1.0 million in Q4 2025 due to a revised long-term sales forecast.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative filing due to the substantial increase in net loss, minimal revenue growth, declining gross margins, and rising G&A expenses, despite ongoing product development and strategic initiatives.

Positives

• Service revenue demonstrated strong growth, increasing by 21% to $57.3 million in 2025, driven by an expanding installed base of instruments and expiring warranties.
• The company continues to innovate with new product launches, including the Cytek Aurora Evo system (May 2025) and the Cytek Muse Micro cell analyzer (March 2025).
• The Enhanced Small Particle (ESP) Detection Option was expanded to the Cytek Aurora CS system in November 2024, broadening application capabilities.
• The Northern Lights-CLC system received regulatory approval for clinical use in the European Union (November 2023) and China, opening new market opportunities.
• Material weaknesses in internal control over financial reporting identified in 2024 were successfully remediated by December 31, 2025, indicating improved financial governance.
• New manufacturing facilities commenced operations in Singapore (March 2025) and Wuxi, China (January 2024), aiming to enhance supply chain resilience and capacity.

Negatives

• Net loss significantly widened to $66.5 million in 2025 from $6.0 million in 2024, primarily due to a $33.1 million valuation allowance against deferred tax assets and lower gross profit.
• Total revenue growth was nearly flat at 1% year-over-year, with product revenue declining by 6%.
• Gross margin decreased to 52% in 2025 from 55% in 2024, impacted by higher tariff costs and increased production overhead.
• General and administrative expenses increased substantially by 37% to $58.9 million, largely due to higher patent litigation expenses.
• Cash and cash equivalents and short-term investments decreased by $16.4 million in 2025.
• The legal settlement liability reduction of $1.0 million was based on a revised *lower* long-term sales forecast, indicating reduced future revenue expectations for certain products.
• The $150 million at-the-market (ATM) offering program expired in August 2025 without any sales, suggesting an inability to raise capital through this mechanism.

Risks

• Limited operating history and recent commercial product launches make it difficult to evaluate future viability and predict performance.
• High dependence on a limited number of core product offerings (Cytek Aurora, Northern Lights, Aurora CS, Aurora Evo) makes revenue prone to fluctuations and long sales cycles.
• Reliance on single or sole source suppliers for key components (lasers, semiconductors) could lead to supply interruptions and increased costs.
• Inability to accurately forecast customer demand and manage inventory could result in shortages or excesses, impacting gross margin and customer relationships.
• International operations and expansion expose the company to business, regulatory, political, operational, financial, and economic risks, including foreign currency fluctuations.
• Tariffs and other government trade policies, such as new U.S. license requirements for exports of high-parameter flow cytometers to China (January 2025), may adversely affect business and demand.
• Limited manufacturing experience and potential quality issues, defects, or recalls could increase costs and reduce net sales.
• Future success is dependent on increasing penetration in existing markets and expanding into adjacent markets, which may not develop as expected.
• Dependence on research and development spending by academic and government institutions, which could be reduced by budgetary constraints.
• Competition in the cell analysis and life sciences tools market is significant, with larger, more established competitors.
• Failure to successfully develop new products, adapt to technological change, or respond to competitor introductions could harm the business.
• Acquisitions or joint ventures may negatively affect operating results, dilute ownership, or incur significant expense.
• Inability to successfully expand commercial operations, including hiring qualified sales and support staff, could adversely affect business.
• Difficulty managing organizational growth could harm future revenue and operating results.
• If information technology systems or data are compromised, the company could experience adverse consequences including regulatory actions, litigation, and reputational harm.
• Products may become subject to more onerous FDA or other regulatory agency regulations, increasing costs and delaying sales.
• Product recalls, whether voluntary or mandated, could have a significant adverse impact on the company.
• Misuse or off-label use of products could harm reputation or result in product liability suits.
• Stringent and changing U.S. and foreign data privacy and security laws (e.g., GDPR, CCPA, PIPL, NIS2) could lead to investigations, fines, and business disruptions.
• Exposure to U.S. and foreign anti-corruption and anti-money laundering laws (e.g., FCPA) can lead to criminal liability and other serious consequences.
• Disruptions at government agencies (FDA, SEC) from funding cuts or shutdowns could hinder their ability to perform functions on which the business relies.
• Issues in the development and use of artificial intelligence technologies, combined with an uncertain regulatory environment, may result in reputation harm or liability.
• Failure to comply with U.S. federal and state fraud and abuse and other healthcare laws and regulations could lead to substantial penalties.
• Inability to obtain and maintain patent or other intellectual property protection, or third-party claims of infringement, could harm the business.
• Concentration of common stock ownership among executive officers, directors, and principal stockholders may prevent new investors from influencing corporate decisions.
• Stock price volatility and broad market fluctuations may negatively impact the market price of common stock.
• Inaccurate estimates or judgments relating to critical accounting policies could cause operating results to fall below expectations.
• Securities class action litigation could result in substantial costs and diversion of management attention.
• Increased costs of operating as a public company and management time devoted to compliance.
• Failure to meet Nasdaq's continued listing requirements could result in delisting.
• Negative or inaccurate research by securities or industry analysts could cause stock price and trading volume to decline.
• Limitations on the ability to use net operating losses (NOLs) to offset future taxable income.
• Changes in effective tax rate or tax liability due to various factors, including changes in tax laws.

Future Outlook

The company expects expenses to increase substantially due to investments in personnel, commercial infrastructure, R&D, geographic expansion, intellectual property protection, and strategic investments. Recurring revenue is anticipated to grow as the installed base of instruments expands. The company plans to pursue regulatory approvals for clinical use of certain products in the United States and continue investing in new product development and enhancements. The long-term sales forecast for products subject to the BD settlement has been revised downwards due to current macroeconomic conditions and headwinds.

Management Comments

• Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications.
• We believe that our innovative FSP and targeted cell isolation technology has the potential to accelerate scientific discovery and have a profound impact on the understanding of cell biology, immunotherapy, and targeted therapeutic approaches (personalized medicine).
• We believe our financial results reflect the continued market demand for our product offerings and adoption of our FSP technology: our strong financial profile is differentiated by the combination of our scaled revenue base, revenue growth and cash balance.
• We expect our expenses will increase substantially in connection with our ongoing activities, as we: attract, hire and retain qualified personnel; invest in processes, commercial infrastructure and supporting functions to scale our business and introduce new products and services; support our research and development efforts; continue to expand geographically; protect and defend our intellectual property; and make strategic investments in complementary businesses, services, products or technologies.
• We expect recurring revenue on an absolute basis to increase and become an increasingly important contributor to our revenue as our installed base expands.
• The Company is focused on controlling our general and administrative expenses; however these may increase in absolute dollars in future periods.
• As of December 31, 2025, the Company's management asserted that it was their intent to indefinitely reinvest unremitted foreign earnings for all its foreign entities.

Industry Context

StockSavvy.ai notes that Cytek Biosciences operates in the highly competitive and rapidly evolving cell analysis and life sciences tools market. The company's focus on Full Spectrum Profiling (FSP) technology aims to address limitations of conventional flow cytometry by offering higher multiplexing and sensitivity. The expansion into clinical research applications, particularly in disease detection and personalized medicine, aligns with broader industry trends towards deep cellular analysis and multi-omics applications. However, the industry is also characterized by significant R&D spending, intense competition from established players like Agilent, Beckman Coulter, and Thermo Fisher Scientific, and increasing regulatory scrutiny, which could impact Cytek's market penetration and profitability.

Comparison to Industry Standards

• Cytek's FSP technology, enabling 50 different colors/biomarkers in a single tube, offers a higher level of multiplexing compared to conventional flow cytometry, which historically had limited dimensionality.
• The Cytek Aurora Evo system's high-throughput capabilities at 200 L/min and resolution of particles down to 70 nm with the ESP Detection Option position it competitively against other high-capacity sorters and small particle analysis tools in the market.
• The company's strategy to integrate its platform with complementary technologies like Next-Generation Sequencing (NGS) for applications such as MRD testing is in line with the industry's move towards comprehensive, multi-modal single-cell analysis solutions, aiming to provide deeper insights than single-technique approaches.

Corporate Governance

Legal Proceedings

• Beckman Coulter, Inc. sued Cytek on August 14, 2024, alleging infringement of U.S. Patent Nos. 10,330,582 and 11,703,443 related to flow cytometers.
• Beckman Coulter filed a first amended complaint on January 9, 2025, further alleging infringement of U.S. Patent Nos. 12,174,106 and 12,174,107.
• Cytek filed an answer denying liability and including counterclaims for false marking against Beckman Coulter.
• Claim construction hearings were held on August 21, 2025, and September 17, 2025, leading to Beckman Coulter dropping all asserted claims from U.S. Patent No. 12,174,106.
• Briefing on dispositive motions is scheduled for March and April 2026, with a trial scheduled for August 17, 2026.
• The company intends to vigorously defend itself and pursue available remedies in the Beckman Coulter lawsuit.

Stakeholder Impact

• **Shareholders**: Experienced significant dilution of ownership interest from previous equity offerings and may face further dilution if additional capital is raised. The substantial net loss and declining stock price could negatively impact investment returns. Share repurchase programs aim to return capital and minimize dilution but have not prevented stock price decline.
• **Employees**: The company is focused on attracting and retaining qualified personnel, offering comprehensive compensation and professional growth opportunities. However, rapid expansion could strain the organization, and competition for skilled personnel is intense. A security incident in November 2025 affected employee personal information, posing a risk to employee trust and data security.
• **Customers**: Benefit from new product introductions like the Cytek Aurora Evo and Muse Micro, and expanded capabilities like the ESP Detection Option. The company aims to provide integrated workflow solutions and customer support. However, product defects or performance issues could lead to dissatisfaction and loss of business.
• **Suppliers**: The company relies on a limited number of suppliers, including single and sole sources, for key components. Any disruptions or changes in supplier relationships could impact manufacturing and product availability.
• **Regulatory Authorities**: The company is subject to extensive regulation by the FDA and other U.S. and foreign governmental agencies. Non-compliance or increased scrutiny could lead to fines, penalties, product recalls, and operating restrictions.

Next Steps

• Continue to invest in commercial infrastructure by hiring additional qualified sales representatives, technical applications specialists, and customer support staff.
• Further expand sales and marketing efforts globally to drive commercialization of products.
• Continue to invest in research and development to develop new products and enhance existing instruments and technologies.
• Pursue regulatory approvals for clinical use of certain products in the United States.
• Generate supporting publications and data to facilitate clinical market penetration in the United States.
• Reassess the approach to manage foreign currency risk as international operations grow.
• Participate in briefing on dispositive motions in the Beckman Coulter lawsuit in March and April 2026.
• Prepare for the trial in the Beckman Coulter lawsuit scheduled for August 17, 2026.
• Manage ongoing credit agreements and potential future withdrawals/repayments of loans in China.

Key Dates

Recommendation

The company's financial performance for 2025 is significantly worse than the prior year, marked by a substantial increase in net loss to $66.5 million and a decline in gross margin to 52%. Revenue growth was negligible at 1%, with product sales actually decreasing. The significant rise in general and administrative expenses, partly due to patent litigation, further pressures profitability. While there are new product launches and strategic initiatives, these have not yet translated into improved financial results. The ongoing patent infringement lawsuit with Beckman Coulter and the expiration of the ATM offering without capital raised add to the uncertainty and risk profile. Given the deteriorating financial health and significant headwinds, a seasoned investor would likely recommend a strong sell.

Keywords

Cell Analysis, Flow Cytometry, Full Spectrum Profiling, FSP Technology, Biomedical Research, Clinical Applications, Cytek Aurora, Northern Lights, Cytek Aurora Evo, Aurora CS, Reagents, SpectroFlo Software, SEC Filing, 10-K, Biotechnology, Life Sciences, Immunology, Oncology, Infectious Diseases, Imaging Flow Cytometry, Amnis, Guava, Muse Cell Analyzer, Enhanced Small Particle Detection, Extracellular Vesicles, MRD Testing, Personalized Medicine, Corporate Governance, Risk Management, Financial Reporting